Trial · NCT04910568
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended Phase II Dose (RP2D) | Baseline up to approximately 4 years | |
| Primary | Percentage of Participants with Adverse Events | Baseline up to approximately 4 years | |
| Primary | Percentage of Dose Interruptions | Baseline up to approximately 4 years | |
| Primary | Percentage of Dose Reductions | Baseline up to approximately 4 years | |
| Primary | Percentage of Dose Intensity | Baseline up to approximately 4 years | |
| Primary | Percentage of Treatment Discontinuation | Baseline up to approximately 4 years | |
| Secondary | Objective Response Rate (ORR) | Baseline up to approximately 4 years | |
| Secondary | Complete Response/Stringent Complete Response (CR/sCR) Rate | Baseline up to approximately 4 years | |
| Secondary | Rate of Very Good Partial Response (VGPR) or Better | Baseline up to approximately 4 years | |
| Secondary | Progression-free Survival (PFS) | Start of study treatment to first date of disease progression or death from any cause, whichever occurs first (up to approximately 4 years) | |
| Secondary | Duration of Response (DOR) | From first partial response (PR) or better until the first date of disease progression or death from any cause, whichever occurs first (up to approximately 4 years) | |
| Secondary | Time to First Response (for Participants who Achieve a Response of Partial Response (PR) or Better) | Baseline up to approximately 4 years | |
| Secondary | Time to Best Response (for Participants who Achieve a Response of PR or Better) | Baseline up to approximately 4 years | |
| Secondary | Overall Survival (OS) | Baseline up until death from any cause (up to approximately 4 years) | |
| Secondary | Serum Concentration of Cevostamab at Specified Timepoints | Cevostamab Pre-Phase (CPP) Day (D) 1 up to approximately 3 years | |
| Secondary | Total Exposure (Area Under the Concentration-time Curve [AUC]) of Cevostamab | CPP D1 up to approximately 4 years | |
| Secondary | Maximum Observed Serum Concentration (Cmax) of Cevostamab | CPP D1 up to approximately 4 years | |
| Secondary | Minimum Observed Serum Concentration (Cmin) of Cevostamab | CPP D1 up to approximately 4 years | |
| Secondary | Clearance of Cevostamab | CPP D1 up to approximately 4 years | |
| Secondary | Volume of Distribution at Steady State of Cevostamab | CPP D1 up to approximately 4 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04910568/registered